Daiichi Sankyo Company, Limited (DSNKY) Discusses ESMO 2025 Highlights With Focus on Key Breast Cancer Trial Data and Regulatory Submissions Transcript

Group 1 - The event is focused on Daiichi Sankyo's ESMO 2025 highlights, moderated by Kentaro Asakura, who is the Corporate Officer and Head of Corporate Communications [1] - The presentation will be conducted in English, with a Q&A session available in both English and Japanese, supported by simultaneous interpretation [2] - Presenters include Dr. Ken Takeshita, Head of Global R&D, and Dr. Abderrahmane Laadem, Head of Late-Stage Clinical Development, with a recording of the event being made [3]